In order to narrow the gap between bench and bedside, the clinical potential of CD8α ALN-1 as a therapeutic cancer vaccine adjuvant should therefore be further evaluated in orthotopically growing tumor models and patient-derived xenografts. The gene discussed is CD8A; the disease is cancer.